Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | BCL9 | O00512 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050779 | 0.87 | GAA (0.56) | GAAALDH1A1SMN1; SMN2ACHESLC6A4 | |
| SCHEMBL27548321 | 0.81 | GAA (0.56) | GAAALDH1A1SMN1; SMN2ACHESLC6A4 | |
| SCHEMBL3047732 | 0.78 | GAA (0.49) | GAAALDH1A1SMN1; SMN2ACHESLC6A4 | |
| SCHEMBL25181638 | 0.76 | GAA (0.71) | GAAALDH1A1SMN1; SMN2ACHESLC6A4 | |
| SCHEMBL27548338 | 0.72 | GAA (0.50) | GAAALDH1A1SMN1; SMN2BCL9CTNNB1 | |
| SCHEMBL7329621 | 0.71 | GAA (0.52) | GAAALDH1A1SMN1; SMN2ACHESLC6A4 | |
| SCHEMBL21410733 | 0.71 | GAA (0.71) | GAAALDH1A1SMN1; SMN2ACHESLC6A4 | |
| SCHEMBL1461897 | 0.71 | ELANE (0.60) | GAAALDH1A1SMN1; SMN2BCL9CTNNB1 | |
| SCHEMBL27818584 | 0.71 | GAA (0.50) | GAAALDH1A1SMN1; SMN2BCL9CTNNB1 | |
| SCHEMBL3050780 | 0.70 | GAA (0.54) | GAAALDH1A1SMN1; SMN2ACHESLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772190-B2 | Didepsipeptide-based endoparasiticides, new didepsipeptides and process for preparing the same | BAYER ANIMAL HEALTH GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-20040034048-A1 | Didepsipeptide-based endoparasiticides, new didepsipeptides and process for preparing the same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-02-19 | — | — | US | disclosed |
| US-20020142969-A1 | DIDEPSIPEPTIDE-BASED ENDOPARASITICIDES, NEW DIDEPSIPEPTIDES AND PROCESS FOR PREPARING THE SAME | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034048-A1 | Didepsipeptide-based endoparasiticides, new didepsipeptides and process for preparing the same | VIP, NGLY1, NPEPPS | GAA 473/4885ALDH1A1 4873/4885SMN1; SMN2 4170/4885 |
| US-20020142969-A1 | DIDEPSIPEPTIDE-BASED ENDOPARASITICIDES, NEW DIDEPSIPEPTIDES AND PROCESS FOR PREPARING THE SAME | VIP, NGLY1, NPEPPS | GAA 479/4885ALDH1A1 4871/4885SMN1; SMN2 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.